Cooper Companies (NASDAQ:COO) Azioni

COOPER COS INC/THE

Cooper Companies

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.

The Cooper Companies, Inc. - Common Stock

The Cooper Companies Inc

Traeger Inc

Corner Growth Acquisition Corp Ordinary Shares - Class A

Corner Growth Acquisition Corp

Corner Growth Acquisition Corp Units (1 Ord Class A & 1/3 War)

Corner Growth Acquisition Corp Warrants (01/01/2027)

Mr. Cooper Group Inc

Carbios SA

Australian Oilseeds Holdings Limited - Ordinary Shares

Australian Oilseeds Holdings Ltd

Australian Oilseeds Holdings Limited - Warrant

Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $92.5, with a high estimate of $105.00 and a low estimate of $76.00. Experiencing a 14.49% decline, the current average is now lower than the previous average price target of $108.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1752699638_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Cooper Companies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$97.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$76.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Cooper Companies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Cooper Companies compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Cooper Companies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Cooper Companies's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cooper Companies analyst ratings.</a>
<h2>All You Need to Know About Cooper Companies</h2>
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
<h3>A Deep Dive into Cooper Companies's Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3M period, Cooper Companies showcased positive performance, achieving a revenue growth rate of 6.33% as of 30 April, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Cooper Companies's net margin is impressive, surpassing industry averages. With a net margin of 8.75%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Cooper Companies's ROE excels beyond industry benchmarks, reaching 1.07%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Cooper Companies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.71% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.31, Cooper Companies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

6 Analysts Have This To Say About Cooper Companies

Mizuho analyst Anthony Petrone maintains Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Outperform and lowers the price target from $105 to $90.

News

Price Target

Mizuho Maintains Outperform on Cooper Companies, Lowers Price Target to $90

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst David Saxon upgraded the rating for The Cooper Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) from Hold to Buy and maintained the price target of $94. Cooper Companies shares closed at $69.74 on Monday. <a href="https://www.benzinga.com/quote/COO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Alan Gould upgraded Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) from Hold to Buy and raised the price target from $80 to $100. Roku shares closed at $82.17 on Monday. <a href="https://www.benzinga.com/quote/ROKU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Ashwani Verma upgraded the rating for Alkermes plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) from Neutral to Buy and raised the price target from $33 to $42. Alkermes shares closed at $29.42 on Monday. <a href="https://www.benzinga.com/quote/ALKS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying COO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/COO/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17091642/image-263-1024x573.png" alt="" class="wp-image-952273" style="width:718px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17091642/image-263-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17091642/image-263-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17091642/image-263-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17091642/image-263.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45968628/wall-streets-most-accurate-analysts-weigh-in-on-3-financial-stocks-with-over-15-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Financial Stocks With Over 15% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Markets

Trading Ideas

ALKS

ROKU

This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $93.0, a high estimate of $105.00, and a low estimate of $76.00. A 14.52% drop is evident in the current average compared to the previous average price target of $108.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1750165243_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Cooper Companies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$97.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$76.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cooper Companies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cooper Companies compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Cooper Companies's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Cooper Companies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cooper Companies analyst ratings.</a>
<h2>About Cooper Companies</h2>
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
<h3>Unraveling the Financial Story of Cooper Companies</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Cooper Companies's revenue growth over a period of 3M has been noteworthy. As of 30 April, 2025, the company achieved a revenue growth rate of approximately 6.33%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Cooper Companies's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.75%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Cooper Companies's ROE stands out, surpassing industry averages. With an impressive ROE of 1.07%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.71%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.31, Cooper Companies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 5 Analysts Discuss Cooper Companies Stock

Needham analyst David Saxon upgrades Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) from Hold to Buy and maintains the price target from $94 to $94.

Needham Upgrades Cooper Companies to Buy, Maintains Price Target to $94

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>Summit Therapeutics Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock declined 29.32% after the company announced topline results <a href="https://www.benzinga.com//node/45693375" target="_blank" rel="noreferrer noopener">from its Phase 3 HARMONi trial</a>.</li>
<li>Temu parent PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) shares tumbled 19.44%  after President Trump said China had violated its agreement with the U.S. Additionally, a federal appeals court on Thursday temporarily reinstated most of<a href="https://www.benzinga.com//node/45696218" target="_blank" rel="noreferrer noopener"> the tariffs imposed by Trump</a>.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) shares fell 17.86% after the company and Sanofi said the AERIFY-1 study met its primary endpoint, <a href="https://www.benzinga.com//node/45692578" target="_blank" rel="noreferrer noopener">but the AERIFY-2 study did not</a>.</li>
<li>Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) dipped 17.72% after Barclays maintained an Equal-Weight rating on the stock and lowered its <a href="https://www.benzinga.com//node/45657176" target="_blank" rel="noreferrer noopener">price forecast from $140 to $120</a>.</li>
<li>Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) stock declined 16.74% after the company reported first-quarter financial results and provided cautious forward-looking commentary. Multiple analysts also lowered<a href="https://www.benzinga.com//node/45651210" target="_blank" rel="noreferrer noopener"> price forecasts following the report</a>.</li>
<li>Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) shares were down 16.31%, possibly amid overall market strength, after President Trump had delayed 50% EU tariffs until July.</li>
<li>Copart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) dipped 15.13% last week. The stock continued its decline after reporting a <a href="https://www.benzinga.com//node/45574729" target="_blank" rel="noreferrer noopener">third-quarter revenue miss</a>.</li>
<li>The Cooper Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) shares decreased 13.90% despite a <a href="https://www.benzinga.com//node/45681308" target="_blank" rel="noreferrer noopener">second-quarter earnings beat</a>. JP Morgan downgraded the stock from Overweight to Neutral and lowered its price forecast from <a href="https://www.benzinga.com/quote/coo/analyst-ratings" target="_blank" rel="noreferrer noopener">$110 to $76</a>.</li>
<li>Texas Pacific Land Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>) stock fell 12.89%.</li>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) stock was down 12.63% after it reported mixed second-quarter earnings and cut its outlook. Additionally, several firms cut their respective <a href="https://www.benzinga.com//node/45698612" target="_blank" rel="noreferrer noopener">price forecasts on the stock</a>.</li>
<li>Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) stock declined 11.90% after its <a href="https://www.benzinga.com//node/45674314" target="_blank" rel="noreferrer noopener">first-quarter results</a>. Additionally, several firms revised their respective <a href="https://www.benzinga.com/quote/burl/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecasts on the stock</a>.</li>
</ol>
Image Via Shutterstock

Large Cap

Movers

BURL

CPRT

DECK

OKTA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

REGN

SMMT

Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio?

Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) reported second-quarter adjusted earnings of 96 cents per share on Thursday, up 14% year over year, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 93 cents</a>.
The medical device company reported sales of $1.00 billion, beating the consensus of $995.35 million.
Sales were up 6% from last year&#8217;s second quarter, 7% in constant <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45681308/coopercompanies-announces-second-quarter-2025-results" rel="noreferrer noopener">currency, 7% organically</a>.
<ul class="wp-block-list">
<li>The CooperVision segment, focused on contact lenses, reported sales of $669.6 million, up 5% from last year&#8217;s second quarter, 7% in constant currency and 7% organically.</li>
<li>CooperSurgical, focused on fertility and women&#8217;s healthcare, reported revenue of $332.7 million, up 8% from last year&#8217;s second quarter, 9% in constant currency and 7% organically.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45677512/alcon-secures-first-fda-approval-since-novartis-spin-off-in-2019" rel="noreferrer noopener">Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019</a>
The gross margin is 68% compared with 67% in last year&#8217;s second quarter, driven by efficiency gains and mix. On a non-GAAP basis, the gross margin was 68%, up from 67% last year.
Operating margin of 18% compared with 17% in last year&#8217;s second quarter, driven by stronger gross margins and targeted expense leverage. On a non-GAAP basis, the operating margin was 25%, up from 24% last year.
Guidance: Cooper Companies revised its fiscal 2025 revenue guidance from $4.08 billion-$4.16 billion to $4.11 billion-$4.15 billion versus a consensus of $4.12 billion.
<ul class="wp-block-list">
<li>The company expects 2025 organic growth of 5%-6%, <a href="https://www.benzinga.com/pressreleases/25/03/g44179753/coopercompanies-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">down from 6%-8%</a>.</li>
<li>CooperVision revenue of $2.76 billion-$2.79 billion (organic growth of 6% to 7%), <a href="https://www.benzinga.com/pressreleases/25/03/g44179753/coopercompanies-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">compared to prior guidance</a> of $2.73 billion-$2.79 billion (organic growth of 6.5% to 8.5%).</li>
<li>CooperSurgical revenue of $1.35 billion-$1.36 billion (organic growth of 3.5% to 4.5%) compared to prior guidance of $1.35 billion-$1.37 billion (organic growth of 4% to 6%).</li>
</ul>
Cooper Companies revised its fiscal 2025 adjusted earnings from $3.94-$4.02 to $4.05-$4.11, compared to the consensus of $3.99.
Analyst Reaction:
<ul class="wp-block-list">
<li>William Blair writes, &#8220;In short, while the market outlook commentary is disappointing and raises some new questions, we believe the company has sufficient tailwinds to drive continued earnings outperformance.&#8221; 
<ul class="wp-block-list">
<li>Analyst Margaret Kaczor Andrew writes that despite the in-line quarter, management lowered market growth expectations by 100 basis points at the midpoint, which is now closer to historical pre-COVID growth levels. The change is due to softer channel inventory dynamics and industry-wide changes in overall purchasing patterns.</li>
<li>William Blair <a href="https://www.benzinga.com/quote/COO/analyst-ratings" target="_blank" rel="noreferrer noopener">maintains an Outperform rating</a>.</li>
</ul>
</li>
<li>Wells Fargo maintains Cooper Companies with an Overweight, lowering the price target from $118 to $93.</li>
<li>JP Morgan downgrades Cooper Companies from Overweight to Neutral and lowers the price target from $110 to $76.</li>
</ul>
Price Action: COO stock was down 14.3% at $68.50 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45680165/meta-hits-1-billion-monthly-ai-users-eyes-future-with-subscriptions" target="_blank" rel="noreferrer noopener">Meta Hits 1 Billion Monthly AI Users, Eyes Future With Subscriptions</a></li>
</ul>
Photo: Shutterstock

Health Care

Why Is Contact Lens Maker Cooper Companies Stock Trading Lower On Friday?

Baird analyst Jeff Johnson maintains Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Outperform and lowers the price target from $107 to $97.

Baird Maintains Outperform on Cooper Companies, Lowers Price Target to $97

A strong May for U.S. equities is closing on a sour note, after President Donald Trump accused China of "totally" breaching a tariff agreement, raising new <a href="https://www.benzinga.com/cannabis/25/05/45693219/feds-favorite-inflation-gauge-slows-but-trumps-china-accusation-flips-market-mood">fears over trade disputes.</a>
The White House is reportedly planning broader tech sanctions against China, with a proposed rule targeting companies majority-owned by already-sanctioned firms. According to people familiar with the matter, these firms would face new licensing conditions from the U.S. government, heightening pressure on Beijing. 
Friday&#8217;s economic reports offered mixed signals. Although inflation showed signs of cooling, consumers pulled back on monthly spending, signaling weakening demand. Personal spending growth slowed to 0.2% in April, a sharp deceleration from 0.7% in March.
Meanwhile, Main Street is sending warning signals, as consumer sentiment remained deeply depressed, holding at a three-year low, according to the<a href="https://www.benzinga.com/markets/economic-data/25/05/45697983/consumer-sentiment-stuck-at-3-year-lows-as-inflation-fears-hit-44-year-high"> University of Michigan's final May reading.</a> Moreover, year-ahead inflation expectations jumped to 4.5%, the highest since 1981.
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) was the worst performer among the mega-cap names, sliding 4% and fully erasing the gains it had notched following Wednesday&#8217;s stronger-than-expected earnings release.
The broader market mirrored the decline. The S&amp;P 500 fell 1% to 5,858 points, while the tech-heavy Nasdaq 100 tumbled 1.3% to 21,100—both marking their lowest levels of the week.
Only defensive sectors such as consumer staples and utilities managed to stay above water, as investors rotated into perceived safe havens amid geopolitical and economic unease.
Crude oil prices declined 1.5% to $60 a barrel amid speculation that OPEC+ could consider a production hike larger than the 410,000 barrels-per-day increase already planned. The group is set to meet Saturday.
Gold, often seen as a haven during market stress, failed to gain traction and dropped 0.9% to trade below $3,300 per ounce.
Cryptocurrency markets also faced headwinds. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) sank below $105,000, hitting its lowest level since May 20.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,015.10</td>
<td>-0.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,858.41</td>
<td>-1.0%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,054.65</td>
<td>-1.0%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,105.32</td>
<td>-1.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:45 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 1% to $584.56.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.5% to $420.37.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 1.3% to $513.31.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) slipped 1% to $204.09.</li>
<li>The&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) outperformed, up 0.7%; the&nbsp;Technology&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 1.6%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul class="wp-block-list">
<li>Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) up 3.60%</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) down 3.33%</li>
<li>Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) up 8.24%</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) up 11.13%</li>
<li>NetApp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) down 0.57%</li>
<li>The Cooper Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) down 14.60%</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPS#NYSE">GPS</a>) down 19.18%</li>
</ul>
Read now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/05/45696827/bitcoin-banks-brokers-will-decide-next-big-market-move-says-bofas-hartnett">Bitcoin, Banks, Brokers Will Decide Next Big Market Move, Says BofA&#8217;s Hartnett </a></li>
</ul>
Photo: Shutterstock

Equities

$BTC

COST

DELL

SPDR Dow Jones Industrial Average ETF Trust

NTAP

NVDA

ULTA

Select Sector SPDR-Consumer Discretionary

Wall Street Slumps As Trump Reignites China Trade Tensions, Nvidia Wipes Out Earnings Rally: What's Driving Markets Friday?

WIIM

Cooper Companies shares are trading lower despite a Q2 earnings beat. JP Morgan downgraded the stock from Overweight to Neutral and lowered its price target from $110 to $76 following the report.

Piper Sandler analyst Jason Bednar reiterates Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Overweight and lowers the price target from $115 to $105.

Reiteration

Piper Sandler Reiterates Overweight on Cooper Companies, Lowers Price Target to $105

Wells Fargo analyst Larry Biegelsen maintains Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Overweight and lowers the price target from $118 to $93.

Wells Fargo Maintains Overweight on Cooper Companies, Lowers Price Target to $93

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Friday.
Shares of Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/ESTC/earnings">fourth-quarter results.</a>
Elastic posted adjusted earnings of 47 cents per share, beating market estimates of 37 cents per share. The company's sales came in at $388.43 million versus expectations of $380.36 million.
Elastic said it sees first-quarter adjusted EPS of 41 to 43 cents on sales of $396.00 million to $398.00 million.
Elastic shares dipped 9.7% to $83.23 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) dipped 13.7% to $24.10 in pre-market trading after the company reported first-quarter financial results and warned tariffs could result in a gross estimated incremental cost of approximately $250 million to $300 million.</li>
<li>The Cooper Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) declined 10% to $72.00 in pre-market trading following second-quarter results.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) shares fell 8.8% to $552.00 in pre-market trading after the company and Sanofi said the AERIFY-1 study met its primary endpoint but the AERIFY-2 study did not.</li>
<li>Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) fell 8.2% to $20.49 in pre-market trading. Newsmax filed for resale of up to 121 million shares of Class B common stock by selling stockholder.</li>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) declined 7.4% to $40.01 in pre-market trading.</li>
<li>American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) fell 7.2% to $10.38 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Venu Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VENU#NASDAQ">VENU</a>) dipped 6.1% to $12.10 in pre-market trading after gaining 8% on Thursday. Venu Holding recently announced it will join the Russell 3000 Index.</li>
<li>NetApp, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) dipped 5.2% to $94.00 in pre-market trading after the company issued soft first-quarter guidance.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45691209/top-3-materials-stocks-that-could-blast-off-this-month-2">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

ESTC

IONQ

NMAX

VENU

Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session

JP Morgan analyst Robbie Marcus downgrades Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) from Overweight to Neutral and lowers the price target from $110 to $76.

Downgrades

JP Morgan Downgrades Cooper Companies to Neutral, Lowers Price Target to $76

Fiscal Year 2025 Financial Guidance
The Company updated its fiscal year 2025 financial guidance. Details are summarized as follows:
<ul>
<li>Fiscal 2025 total revenue of $4,107 - $4,146 million (organic growth of 5% to 6%) 
<ul>
<li>CVI revenue of $2,759 - $2,786 million (organic growth of 6% to 7%)</li>
<li>CSI revenue of $1,347 - $1,359 million (organic growth of 3.5% to 4.5%)</li>
</ul>
</li>
<li>Fiscal 2025 non-GAAP diluted EPS of $4.05 - $4.11</li>
</ul>
Non-GAAP diluted earnings per share guidance excludes amortization and impairment of intangible assets, and certain income or gains and charges or expenses including acquisition and integration costs which we may incur as part of our continuing operations.
With respect to the Company's guidance expectations, the Company has not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses, which are reconciling items between the non-GAAP and GAAP measure. Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, the Company is not able to provide such guidance.

Guidance

Cooper Companies Raises FY2025 Adj EPS Guidance from $3.94-$4.02 to $4.05-$4.11 vs $3.99 Est; Narrows FY2025 Sales Guidance from $4.08B-$4.16B to $4.11B-$4.15B vs $4.12B Est

Cooper Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COO#NYSE">COO</a>) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.93 by 3.23 percent. This is a 12.94 percent increase over earnings of $0.85 per share from the same period last year. The company reported quarterly sales of $1.00 billion which beat the analyst consensus estimate of $995.35 million by 0.70 percent. This is a 6.33 percent increase over sales of $942.60 million the same period last year.

Earnings

Earnings Beats

Cooper Companies Q2 Adj. EPS $0.96 Beats $0.93 Estimate, Sales $1.00B Beat $995.35M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) is expected to report earnings for its first quarter. 
• SpartanNash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPTN#NASDAQ">SPTN</a>) is expected to report quarterly earnings at $0.43 per share on revenue of $2.86 billion. 
• Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) is likely to report quarterly earnings at $1.17 per share on revenue of $170.69 million. 
• Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) is expected to report quarterly loss at $0.22 per share on revenue of $3.06 billion. 
• Movado Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOV#NYSE">MOV</a>) is expected to report quarterly earnings at $0.39 per share on revenue of $142.11 million. 
• Build-A-Bear Workshop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) is likely to report quarterly earnings at $0.87 per share on revenue of $118.90 million. 
• Caleres (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAL#NYSE">CAL</a>) is expected to report quarterly earnings at $0.37 per share on revenue of $622.05 million. 
• Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $1.89 billion. 
• Futu Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) is likely to report earnings for its first quarter. 
• American Woodmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) is likely to report quarterly earnings at $1.42 per share on revenue of $426.24 million. 
• Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) is estimated to report quarterly earnings at $0.47 per share on revenue of $1.42 billion. 
• BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $1.23 billion. 
• Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is expected to report quarterly earnings at $1.09 per share on revenue of $8.82 billion. 
• Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) is projected to report quarterly earnings at $1.43 per share on revenue of $2.53 billion. 
• Hormel Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRL#NYSE">HRL</a>) is projected to report quarterly earnings at $0.34 per share on revenue of $2.90 billion. 
• Royal Bank of Canada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RY#NYSE">RY</a>) is likely to report quarterly earnings at $2.25 per share on revenue of $11.20 billion. 
• Canadian Imperial Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CM#NYSE">CM</a>) is projected to report quarterly earnings at $1.34 per share on revenue of $5.01 billion. 
• Aurora Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) is projected to report earnings for its first quarter. 
• Diana Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSX#NYSE">DSX</a>) is expected to report earnings for its first quarter. 
• Roivant Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) is estimated to report quarterly loss at $0.16 per share on revenue of $62.17 million. 
• Sound Point Meridian Capital, Inc. Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPMC#NYSE">SPMC</a>) is expected to report quarterly earnings at $0.60 per share on revenue of $20.48 million. 
• Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) is projected to report quarterly loss at $0.06 per share on revenue of $103.50 million. 
• Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $7.31 million. 
• BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is estimated to report earnings for its first quarter. 
<h3>Companies Reporting After The Bell</h3>
• Universal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UVV#NYSE">UVV</a>) is estimated to report earnings for its fourth quarter. 
• Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) is expected to report quarterly earnings at $4.21 per share on revenue of $62.85 billion. 
• American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) is estimated to report quarterly earnings at $0.11 per share on revenue of $1.08 billion. 
• Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) is projected to report quarterly earnings at $1.67 per share on revenue of $23.15 billion. 
• Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $374.15 million. 
• Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) is likely to report quarterly earnings at $5.77 per share on revenue of $2.81 billion. 
• Red Robin Gourmet Burgers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRGB#NASDAQ">RRGB</a>) is estimated to report quarterly loss at $0.51 per share on revenue of $388.55 million. 
• PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) is projected to report quarterly earnings at $0.19 per share on revenue of $118.98 million. 
• NGL Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGL#NYSE">NGL</a>) is projected to report earnings for its fourth quarter. 
• Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) is likely to report quarterly earnings at $0.43 per share on revenue of $3.41 billion. 
• Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) is expected to report quarterly earnings at $0.76 per share on revenue of $667.15 million. 
• NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) is expected to report quarterly earnings at $1.90 per share on revenue of $1.72 billion. 
• Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $84.01 million. 
• UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $332.81 million. 
• Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) is likely to report quarterly earnings at $0.93 per share on revenue of $995.81 million. 
• Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) is estimated to report quarterly earnings at $0.61 per share on revenue of $1.88 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALAR

AMBA

AMWD

BBWI

BOSC

DOOO

DXLG

FUTU

HLNE

MRVL

PATH

ROIV

RRGB

SPMC

SPTN

Earnings Scheduled For May 29, 2025

Cooper Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COO#NYSE">COO</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Cooper Companies to report an earnings per share (EPS) of $0.93.
Anticipation surrounds Cooper Companies's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 6.57% drop in the share price the following trading session.
Here's a look at Cooper Companies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.91</td>
<td>1</td>
<td>0.91</td>
<td>0.83</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.92</td>
<td>1.04</td>
<td>0.96</td>
<td>0.85</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>-4.0%</td>
<td>12.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1748440912_0.png" alt="eps graph" />
<h3>Market Performance of Cooper Companies's Stock</h3>
Shares of Cooper Companies were trading at $80.59 as of May 27. Over the last 52-week period, shares are down 11.17%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Insights Shared by Analysts on Cooper Companies</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Cooper Companies.
Cooper Companies has received a total of 5 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $109.4, the consensus suggests a potential 35.75% upside.
<h3>Analyzing Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Align Technology, Solventum and Merit Medical Systems, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Align Technology, with an average 1-year price target of $226.38, suggesting a potential 180.9% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Solventum, with an average 1-year price target of $79.62, suggesting a potential 1.2% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Merit Medical Systems, with an average 1-year price target of $109.57, suggesting a potential 35.96% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for Align Technology, Solventum and Merit Medical Systems, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cooper Companies</td>
<td>Outperform</td>
<td>3.55%</td>
<td>$660.20M</td>
<td>1.29%</td>
</tr>
<tr>
<td>Align Technology</td>
<td>Outperform</td>
<td>-1.82%</td>
<td>$680.11M</td>
<td>2.44%</td>
</tr>
<tr>
<td>Solventum</td>
<td>Neutral</td>
<td>2.68%</td>
<td>$1.11B</td>
<td>4.40%</td>
</tr>
<tr>
<td>Merit Medical Systems</td>
<td>Outperform</td>
<td>9.84%</td>
<td>$172.02M</td>
<td>2.15%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Cooper Companies ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
<h3>Get to Know Cooper Companies Better</h3>
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
<h3>Key Indicators: Cooper Companies's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Cooper Companies's revenue growth over a period of 3 months has been noteworthy. As of 31 January, 2025, the company achieved a revenue growth rate of approximately 3.55%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Cooper Companies's net margin excels beyond industry benchmarks, reaching 10.81%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Cooper Companies's ROE excels beyond industry benchmarks, reaching 1.29%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Cooper Companies's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.85%, the company showcases efficient use of assets and strong financial health.
Debt Management: Cooper Companies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.31.
<a href="https://www.benzinga.com/quote/COO/earnings">To track all earnings releases for Cooper Companies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Cooper Companies's Earnings Potential

Throughout the last three months, 5 analysts have evaluated Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Cooper Companies and provided 12-month price targets. The average target is $109.4, accompanied by a high estimate of $115.00 and a low estimate of $105.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.81%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747915249_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Cooper Companies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$107.00</td>
<td>$117.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cooper Companies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cooper Companies compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Cooper Companies's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Cooper Companies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cooper Companies analyst ratings.</a>
<h2>Delving into Cooper Companies's Background</h2>
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
<h3>Financial Milestones: Cooper Companies's Journey</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3M period, Cooper Companies showcased positive performance, achieving a revenue growth rate of 3.55% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Cooper Companies's net margin is impressive, surpassing industry averages. With a net margin of 10.81%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Cooper Companies's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.29%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.85%, the company showcases effective utilization of assets.
Debt Management: Cooper Companies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.31.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Cooper Companies

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO